Launches

Sun Pharma launches Drizalma Sprinkle in US

Sun Pharmaceutical Industries announced that one of its wholly owned subsidiaries has launched Drizalma Sprinkle (duloxetine delayed-release capsules) in the US for oral use.

Kyowa Kirin launches NOURIANZ in US for treatment of Parkinson’s disease “Off” episodes

Kyowa Kirin, Inc. (Kyowa Kirin), an affiliate of Kyowa Kirin Co., Ltd. (TSE: 4151), announced today that NOURIANZ (istradefylline) is now available in the U.S. as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) experiencing “off” episodes.

Sun Pharma launches CEQUA for treatment of dry eye disease in US

Sun Pharmaceutical Industries announced that one of its wholly-owned subsidiaries has commercialised CEQUA (cyclosporine ophthalmic solution) 0.09% in the US.

Celltrion to launch Temixys double combination once-daily tablet for HIV treatment in US

Celltrion announced that it is launching Temixy in the US, which were approved in November by US Food and Drug Administration (FDA).

Ontario provides access to Biktarvy for treatment of HIV

Gilead Sciences Canada announced that effective July 31, the Ontario Drug Benefit Program will provide eligible patients with access to Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg) tablets, a once-daily single tablet and complete regimen for the treatment of HIV-1 infection in adults. Health Canada granted a Notice of Compliance for BIKTARVY in July 2018.

Alvogen, Lotus launch generic version of Navelbine Softgel capsule in Europe

Alvogen announced that its subsidiary Lotus Pharmaceuticals has launched Vinorelbine 20, 30 and 80mg soft capsules in Europe.

Rising Pharmaceuticals announces the US launch of generic version of Pregabalin Capsules

Rising Pharmaceuticals, a Rising Pharma Holdings Inc. company, today announced the U.S. launch & commercial shipment of a generic version of Lyrica, (pregabalin) Capsules, in all eight commercially available strengths (25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, & 300 mg.

Sun Pharma launches Ezallor Sprinkle in US for people who have difficulty swallowing

Sun Pharmaceutical Industries announced the U.S. launch of Ezallor Sprinkle (rosuvastatin) capsules for the treatment of three types of elevated lipid disorders in people who have difficulty swallowing, a problem that is estimated to affect approximately 30-35% of long-term care residents.

Fresenius Kabi introduces Levothyroxine Sodium Injection Solution

Fresenius Kabi has announced tthe immediate availability in the US of Levothyroxine Sodium Injection Solution in 100mcg per 5mL, 200 mcg per 5mL and 500mcg per 5mL single-dose vials.